Biopharmaceutical company ABVC BioPharma is dramatically increasing its investment in U.S. manufacturing infrastructure, targeting the development of advanced pharmaceutical production capabilities. The company has already invested over $100 million in U.S. operations and plans an additional $120 million investment in cutting-edge production facilities.
ABVC's strategic expansion includes acquiring a California pharmaceutical manufacturing facility for $60 million, which currently supports clinical-stage drug development in oncology, central nervous system disorders, and ophthalmology. The facility specializes in API processing, formulation development, and pharmaceutical packaging, with potential for future commercial scale production.
The company's ambitious plan involves constructing innovative "gigafactories" leveraging advanced technologies such as vertical farming, hydroponic systems, and AI-driven environmental controls. These facilities aim to produce over 1,000 metric tons of botanical raw materials annually, with projected goals of reducing raw material costs by 30% and creating a sustainable, traceable supply chain.
This substantial investment is expected to generate significant economic impact, including creating more than 500 new jobs across research, manufacturing, and quality control operations. ABVC projects product sales could exceed $100 million annually within five years, positioning the company as a potential leader in botanical-based pharmaceutical production.
CEO Uttam Patil emphasized the company's commitment to developing high-quality, plant-based therapies while establishing a secure and efficient global supply chain. The expansion represents a significant strategic move in the biopharmaceutical industry, focusing on innovative production methods and addressing unmet medical needs.
